Baxter licks its wounds as it takes $293 million losses
This article was originally published in Clinica
Executive Summary
Baxter Healthcare Corporation has decided to abandon and write off the expenditure on its blood substitute, HemAssist. At the same time it is making provisions for other misfortunes which have befallen the $6.1 billion company. The total provision in the third quarter will be $293 million.